Anchor
FDA approves Guardant360 Liquid CDx with 100x larger genomic panel
New CapabilitiesBlood-based cancer test now reads both genetic mutations and epigenetic patterns from a single draw
May 20th, 2026: Guardant360 Liquid CDx approvedNew here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
Overview
For most patients with advanced cancer, picking the right targeted drug still starts with a tissue biopsy. On May 20, the FDA approved a blood test that reads 100 times more of the tumor's DNA than the previous version.
The new Guardant360 Liquid CDx, from Guardant Health, looks at both genetic mutations and epigenetic patterns in a single tube of blood. It returns results in about seven days. The seven companion diagnostic uses of its 2020 predecessor carry over to the new test.
Why it matters
If you or someone you love has advanced cancer, this test may replace a tissue biopsy and still pick the right targeted drug.
Questions about this story
No questions yet — be the first to ask.
Key Indicators
100x
Wider genomic footprint
How much more of the tumor genome the new panel reads versus the 2020 Guardant360 CDx.
~7 days
Turnaround time
Roughly how fast oncologists get results after a single blood draw.
7
Companion diagnostic uses retained
Drug-pairing indications carried over from the original Guardant360 CDx.
$2.78B
U.S. liquid biopsy market, 2026
MarketsandMarkets and Towards Healthcare estimates for the current U.S. market.
Related Media
Close-up of a gloved hand handling test tubes with red liquid in a laboratory setting.
Close-up of gloved hands holding a blood test tube with red liquid against a white background.
1.2K views
8:03
FDA Approves Guardant360 CDx delivers critical genomic info ...
OncologyTube
371 views
3:23
Enabling In-Country Liquid Biopsy Testing Around the Globe ...
Guardant Health
27.5K views
2:45
New Blood Test Could Change The Way Cancer Is Detected
NBC News
Images from Openverse under Creative Commons licenses. Videos from YouTube.
Voices
Curated perspectives — historical figures and your fellow readers.
Play
Exploring all sides of a story is often best achieved with Play.
Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict.
Log in
Sign Up
Higher or Lower
A number from this story, against one from elsewhere in the news — guess which is bigger, then keep the chain going. 5 rounds, 3 strikes; a miss costs a strike and resets your streak.
Example
Anchor
EU tariff revenue
$52B
Big for this kind of number
Mystery
Pentagon AI contract
?
Round 1
Streak: 0
Mystery
?
Keyboard: ↓/L lower · ↑/H higher
0 pts
Best streak: 0 · Rounds: 0
0 points — sign up to put that on the leaderboard.
Now try on this story
Timeline
FDA approves Guardant360 Liquid CDx with 100x larger genomic panel
Order five events from this story, oldest at top. Each in the right slot scores 1 — neighbours within one slot count too. Your previous result — green ✓ for exact slots, yellow ~ for off by one. Cards now in true chronological order.
Loading puzzle…
Tap 💡 Free hint to lock the oldest into slot 1 — that leaves just four to order. Type pills are clues.
0/5
Exact slot
0/5
Within 1
Sign up to save your score and track a streak across stories.
Now try on this story
Connections
Sixteen names from the news. Find the four hidden groups of four. Four mistakes max.
Loading today's puzzle…
0/4 groups
Mistakes
Sign up to keep a daily streak — a new puzzle lands every day.
Now try on this story
Exit debate?
Your progress in this debate will be lost.
How it works
- 1 Two AI personas square off on this story.
- 2 You predict who'll win each round — correct picks earn XP.
- 3 One crossfire question is yours to fire. Pick it carefully.
Couldn't generate a topic
Select Your Champions
Choose one persona for each side of the debate
DEBATE TOPIC
Choose personas with different perspectives for a more dynamic debate.
SIDE A (PRO)
Select debater for this side:
No debate personas available right now.
SIDE B (CON)
Select debater for this side:
No debate personas available right now.
VS
Get ready to make your prediction...
Round of
Claim
Evidence
Stakes
Crossfire Answer
Closing Statement
Claim
Evidence
Stakes
Crossfire Answer
Closing Statement
Your Crossfire Question
Generating arguments...
Who's Got This Round?
Make your prediction before the referee scores
The referee scores both sides on
Correct predictions earn +20 XP
· Press 1 or 2 to pick
Evidence
40%
Logic
30%
Detail
20%
Style
10%
Round Results
Your Pick
Not this time
(%)
Overall Score
/10
Your Pick
Not this time
(%)
Overall Score
/10
Set the Crossfire
Pick the question both personas must answer in the final round
Crafting crossfire questions...
Choosing a question earns +10 XP crossfire bonus
🏆
Total XP Earned
Cred Change
Predictions
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
XP Breakdown
Base completion
+20 XP
Rounds played ( rounds x 5 XP)
+ XP
Correct predictions ( correct x 20 XP)
+ XP
Crossfire bonus
+10 XP
Accuracy
%
Prediction History
Round
You picked:
✓
✗
Now try on this story
Keep debating to level up your credibility and unlock achievements
People Involved
Organizations Involved
Guardant Health
Cancer diagnostics company (Nasdaq: GH)
Maker of the newly approved Guardant360 Liquid CDx
Redwood City-based diagnostics company that builds blood-based cancer tests for treatment selection, residual disease monitoring, and screening.
U.S. Food and Drug Administration
Federal regulator
Approved Guardant360 Liquid CDx on May 20, 2026
The federal agency that approves drugs, devices, and diagnostics for U.S. sale.
Timeline
June 2016 May 2026
5 events
Latest: May 20th, 2026 · 3 months ago
Tap a bar to jump to that date
-
Guardant360 Liquid CDx approved
Latest ApprovalThe FDA approved the new Guardant360 Liquid CDx, the largest liquid biopsy panel cleared to date. It reads 100 times the genome of the 2020 version and adds epigenomic profiling.
-
Abbott closes $21B acquisition of Exact Sciences
MarketAbbott Laboratories absorbed Exact Sciences, consolidating one of Guardant's biggest competitors under a large-cap diagnostics owner.
-
Shield approved for colorectal cancer screening
ApprovalGuardant's Shield became the first liquid biopsy approved for cancer screening in average-risk adults.
-
Original Guardant360 CDx approved
ApprovalThe FDA approved the first version of Guardant360 CDx as a companion diagnostic. FoundationOne Liquid CDx was approved the same month.
-
First blood-based cancer genetic test approved
ApprovalThe FDA approved Roche's cobas EGFR Mutation Test v2 to detect EGFR mutations from plasma in non-small cell lung cancer.
Historical Context
3 moments from history that rhyme with this story — and how they unfolded.
June 2016
First blood-based cancer genetic test (2016)
The FDA approved Roche's cobas EGFR Mutation Test v2 to detect EGFR mutations in plasma from non-small cell lung cancer patients. It looked at one gene. Until then, oncologists had to send tissue to a lab to test for the same mutation.
Then
Roche's test gave oncologists a way to pick EGFR-targeted drugs for lung cancer patients without a needle biopsy. Adoption was steady within lung cancer practices.
Now
It established the regulatory template the FDA would use to approve broader liquid biopsy panels four years later.
Why this matters now
The 2026 Guardant approval is the same regulatory category, scaled up by orders of magnitude. cobas read one gene; Guardant360 Liquid CDx now reads hundreds, plus epigenetic markers.
August 2020
Original Guardant360 CDx and FoundationOne Liquid CDx (2020)
Within a month of each other, the FDA approved the first two comprehensive liquid biopsy panels: Guardant360 CDx (August 7) and Foundation Medicine's FoundationOne Liquid CDx (August 26). Both let oncologists profile dozens of cancer-driver genes from a tube of blood.
Then
Liquid biopsy moved from niche to standard option for advanced cancer treatment selection. Insurance coverage followed in lung, breast, and colorectal cancer.
Now
The two tests defined the liquid biopsy companion diagnostic market through 2026. Guardant360 ran on roughly 80 genes; the new 2026 panel claims a footprint 100 times larger.
Why this matters now
The May 2026 approval is the first major upgrade to that 2020-era baseline. It's the same product family, six years later, with AI-driven sequencing and added epigenomic readouts.
July 2024
Shield approved for cancer screening (2024)
The FDA approved Guardant's Shield blood test for colorectal cancer screening in average-risk adults aged 45 and older. It was the first liquid biopsy approved for screening rather than treatment selection.
Then
Shield gave adults a blood-draw alternative to colonoscopy or stool-based testing. CMS issued coverage in 2024.
Now
Shield opened a second, larger market for liquid biopsy: people without cancer. Multi-cancer early detection tests from Grail, Exact Sciences (now Abbott), and others followed.
Why this matters now
Shield is Guardant's screening play; the new Guardant360 Liquid CDx is its treatment-selection play. Together they cover both ends of the cancer care path with blood draws.
Sources
(6)Related Stories
FDA panel weighs blood-test-guided early drug switch for breast cancer
New Capabilities
Updated May 31
Talazoparib trial moves a targeted prostate cancer drug to an earlier stage
New Capabilities
Updated Jul 30
Off-the-shelf cancer cell therapy clears major regulatory hurdle toward replacing custom-made treatments
New Capabilities
Updated May 30
Abbott absorbs Exact Sciences, creating a cancer diagnostics giant
Money Moves
Updated May 30
FDA approves AbbVie's Decnupaz for ultra-rare BPDCN blood cancer
New Capabilities
Updated May 28
FDA approves Bizengri as first targeted drug for rare NRG1-driven bile duct cancer
New Capabilities
Updated May 31